- What we do
-
-
Routes of delivery
- Oral
- Nasal
- Nose to Brain
- Pulmonary
- Parenteral
-
Development stage
- Pre-clinical
- Phase I to Phase II
- Phase III - Commercial
Our Approach
- Choosing Your CDMO Partner
- Project Management
-
- About us
-
-
A CDMO like no other
- About Us
- Our Facilities
- Our History
- Awards and Achievements
-
Leadership Expertise
- Executive Leadership Team
- Board of Directors
- Careers
-
-
- Resources
- Events
- Contact
Nose-to-Brain
Drug Delivery.
Intranasal drug delivery expertise.
Our expertise in spray drying, nasal delivery systems, and CNS-targeted therapeutics makes us the ideal partner for your intranasal drug development journey.
Improve CNS bioavailability
Advantages of Nose to Brain Drug Delivery.
Nose to brain delivery offers a direct, non-invasive route to the central nervous system (CNS), bypassing the blood-brain barrier via the olfactory and trigeminal nerves. This approach enables:
- Rapid onset of action for CNS therapies
- Improved CNS bioavailability of peptides, proteins, and small molecules
- Non-invasive administration without injections
- Targeted delivery for neurological and psychiatric conditions

One route into the brain is to avoid the blood brain barrier altogether through the delivery of drugs directly into the brain following the administration of a drug into the nose.
Dr. Richard Johnson, Chief Scientific Officer

N2B Drug Development
Intranasal Drug Development.
At Upperton, we combine formulation development with delivery technologies to optimise your nasal drug product for brain targeting.
Spray Drying for Nasal Formulations
Our spray drying expertise enables:
- Precise particle engineering for nasal deposition
- Development of dry powder and liquid nasal formulations
- Enhanced stability and bioavailability of sensitive molecules
Device Compatibility & Delivery Optimisation
We ensure your formulation is compatible with a range of nasal delivery devices, including:
- Single-dose and multi-dose nasal sprays
- Dry powder nasal inhalers
- Customised delivery systems for nose-to-brain targeting

Start your next project with Upperton.
As a leading UK-based CDMO our defining traits lie in our adaptability, nimbleness and expertise in oral, nasal and pulmonary dosage forms.
Through our science-led approach we align to your drug development needs from pre-clinical to late phase manufacture, across oral solid dosage forms, liquids, semi-solids, nasal and inhaled products.

Get in touch
Contact Upperton to start developing your nose-to-brain drug product with speed and expertise.